查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1391956

胰島素增敏劑市場：按胰島素增敏劑類型、按適應症、按給藥途徑、按配銷通路、按地區

Insulin Sensitizers Market, By Type of Insulin Sensitizers, By Indication, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球胰島素增敏劑市場規模預計將從2023年的210億美元增加到2030年的324.2億美元，2023-2030年預測期間年複合成長率為6.4%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 210億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 6.40% 2030年市場規模預測 324.2億美元
圖 1. 2023 年胰島素增敏劑的全球市場佔有率（按地區分類）
胰島素增敏劑市場-IMG1

胰島素增敏劑是提高胰島素敏感性和降低血糖值的藥物。這些藥物也被稱為血糖正常劑或降血藥，有助於在不使用胰島素的情況下將血糖值恢復到正常範圍。它們的作用是提高肝臟、肌肉和脂肪細胞對胰島素的敏感性。胰島素增敏劑有多種類型，包括二甲雙胍 (Met)、吡格列酮 (Pio)、噻唑烷 (TZD) 和肌醇。

市場動態

全球胰島素增敏劑市場的成長是由糖尿病（尤其是第2型糖尿病）盛行率不斷上升所推動的。胰島素增敏劑常用於治療第 2 型糖尿病，以提高胰島素敏感性並控制血糖值。肥胖會顯著增加第 2 型糖尿病和胰島素抗性。由於全球肥胖盛行率不斷上升，有效的胰島素增敏劑可以幫助控制與胰島素抗性相關的代謝疾病。正在進行的研究和開發工作正在創造創新的化合物和配方，並推出新的和增強的胰島素增敏劑，以提高治療胰島素敏感性的藥物的功效和安全性。此外，各國政府也採取了多項舉措來對抗糖尿病。其計劃和項目的重點是普及糖尿病知識、早期發現糖尿病以及推廣胰島素增敏劑等必要且負擔得起的治療方法。

與其他藥物一樣，胰島素增敏劑也可能產生副作用，例如體重增加、體液儲存、骨折和心臟衰竭風險增加。某些類別的胰島素增敏藥物，例如噻唑烷 (TZD)，可能會引起人們對其安全性的擔憂，這限制了它們的使用，並使它們難以獲得廣泛接受。

本研究的主要特點

  • 本報告對全球胰島素增敏劑市場進行了詳細分析，並提出了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
  • 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球胰島素增敏劑市場的主要企業。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
  • 全球胰島素增敏劑市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球胰島素增敏劑市場的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 調查目的和假設

  • 研究目標
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
  • 糖尿病盛行率增加
  • 肥胖流行病在全球日益嚴重
  • 藥物開發的進展
  • 政府有利配合措施
    • 抑制因素
  • 副作用和安全問題
  • 對某些患者族群的療效有限
  • 監管挑戰和市場進入
    • 機會
  • 新興國家
  • 個人化醫療
  • 聯合治療
  • 非糖尿病應用
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章 全球胰島素增敏劑市場 - 冠狀冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章 全球胰島素增敏劑市場，依類型，2018-2030

  • 噻唑烷二酮 (TZD)
  • 雙胍類
  • Incretin-based的治療
  • 其他

第6章 全球胰島素增敏劑市場，依適應症分類，2018-2030 年

  • 2型糖尿病
  • 糖尿病前期
  • 卵巢症候群（PCOS）

第7章 全球胰島素增敏劑市場，依給藥途徑，2018-2030

  • 口服
  • 注射

第8章 全球胰島素增敏劑市場，依配銷通路，2018-2030

  • 醫院藥房
  • 零售藥房
  • 線上藥房

第9章 2018-2030年全球胰島素增敏劑市場（按地區）

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東和非洲
  • GCC
  • 以色列
  • 北非
  • 中部非洲
  • 其他中東和非洲

第10章 競爭形勢

  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Takeda Pharmaceutical

第11章章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6069

Global insulin sensitizers market size is projected to reach US$ 32.42 billion by 2030, from US$ 21.00 billion in 2023, at a CAGR of 6.4% during the forecast period 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 21.00 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.40% 2030 Value Projection: US$ 32.42 Bn
Figure 1. Global Insulin Sensitizers Market Share (%), By Region, 2023
Insulin Sensitizers Market - IMG1

Insulin sensitizers are medications that improve insulin sensitivity and reduce blood sugar levels. These are also known as blood sugar normalizing agents and euglycemics, and these help in returning blood glucose to the normal range without using insulin. These work by increasing liver, muscle and fat cells' sensitivity to insulin. There are several different types of insulin sensitizers including metformin (Met), pioglitazone (Pio), thiazolidinediones (TZDs), and inositols.

Market Dynamics

Global insulin sensitizers market growth is driven by increased prevalence of diabetes, especially type 2 diabetes. Insulin sensitizers are frequently used to increase insulin sensitivity and manage blood glucose levels in the treatment of type 2 diabetes. Type 2 diabetes and insulin resistance are both significantly increased by obesity. Effective insulin sensitizer helps in controlling insulin resistance and related metabolic diseases due to rising prevalence of obesity worldwide. The ongoing research and development activities have introduced new and enhanced insulin sensitizers that creates innovative compounds and formulation methods, and improves the efficacy and safety profiles of drugs that treat insulin sensitivity. Furthermore, the governments have taken several initiatives to combat diabetes. The plans and the programs focus on spreading knowledge about diabetes, early detection of diabetes and facilitating necessary and affordable treatments like insulin sensitizers.

Like any drugs, insulin sensitizers have potential side effects like weight gain, fluid retention, bone fractures, and an elevated risk of heart failure. Specific kinds of insulin sensitizers such as thiazolidinediones (TZDs) may create worries about its safety concern, thus, restricting their use and make them difficult to embrace widely.

Key features of the study:

  • This report provides in-depth analysis of the global insulin sensitizers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global insulin sensitizers market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global insulin sensitizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin sensitizers market

Insulin Sensitizers Market Detailed Segmentation:

  • By Type:
    • Thiazolidinediones (TZDs)
    • Biguanides
    • Incretin-based therapies
    • Others
  • By Indication:
    • Type 2 Diabetes
    • Prediabetes
    • Polycystic Ovary Syndrome (PCOS)
  • By Route of Administration:
    • Oral
    • Injectable
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East &Africa
  • Company Profiles:
    • Eli Lilly and Company
    • Novo Nordisk
    • Sanofi
    • Merck & Co.
    • Bristol Myers Squibb
    • AstraZeneca
    • Boehringer Ingelheim
    • Johnson & Johnson
    • Takeda Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Insulin Sensitizers
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of diabetes
  • Growing global obesity epidemic
  • Advancements in drug development
  • Favorable government initiatives
    • Restraints
  • Adverse effects and safety concerns
  • Limited efficacy in certain patient populations
  • Regulatory challenges and market access
    • Opportunities
  • Emerging economies
  • Personalized medicine
  • Combination therapies
  • Non-diabetic applications
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Insulin Sensitizers Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Insulin Sensitizers Market, By Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Thiazolidinediones (TZDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Biguanides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Incretin-based therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Insulin Sensitizers Market, By Indication, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Type 2 Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn )
  • Prediabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Polycystic Ovary Syndrome (PCOS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Insulin Sensitizers Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Insulin Sensitizers Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Insulin Sensitizers Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Insulin Sensitizers, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • North Africa
  • Central Africa
  • Rest of Middle East & Africa

10. Competitive Landscape

  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us